ABEONA THERAPEUTICS INC. Operating Lease, Expense
ABEONA THERAPEUTICS INC. (ABEO) reported Operating Lease, Expense of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. operating lease, expense for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, expense for the quarter ending 2026-03-31 was $300.00K, a 25.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, expense for the quarter ending 2025-12-31 was $700.00K, a 75.00% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, expense for the quarter ending 2025-09-30 was $400.00K, a 33.33% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, expense for fiscal 2025 was $1.70M, a 30.77% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. operating lease, expense for fiscal 2024 was $1.30M, a 8.33% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. operating lease, expense for fiscal 2023 was $1.20M, a 33.33% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. operating lease, expense for fiscal 2022 was $1.80M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-13 | $600.00K 10-Q · filed 2026-08-13 | $1.30M derived: sum of 3 quarters · filed 2026-08-13 | $1.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-13 | $1.00M derived: sum of 2 quarters · filed 2026-05-13 | $1.40M derived: sum of 3 quarters · filed 2026-05-13 | $1.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.10M derived: sum of 2 quarters · filed 2026-03-17 | $1.40M derived: sum of 3 quarters · filed 2026-08-13 | $1.70M 10-K · filed 2026-03-17 |
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-12 | $700.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.00M 10-Q · filed 2025-11-12 | $1.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-13 | $700.00K 10-Q · filed 2026-08-13 | $1.10M derived: sum of 3 quarters · filed 2026-08-13 | $1.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-13 | $800.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.10M derived: sum of 3 quarters · filed 2026-05-13 | $1.40M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $700.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.00M derived: sum of 3 quarters · filed 2026-03-17 | $1.30M 10-K · filed 2026-03-17 |
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-12 | $600.00K derived: sum of 2 quarters · filed 2025-11-12 | $900.00K 10-Q · filed 2025-11-12 | $1.20M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-14 | $600.00K 10-Q · filed 2025-08-14 | $900.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.20M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-15 | $600.00K derived: sum of 2 quarters · filed 2025-05-15 | $900.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.20M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $600.00K derived: sum of 2 quarters · filed 2025-03-20 | $900.00K derived: sum of 3 quarters · filed 2025-03-20 | $1.20M 10-K · filed 2025-03-20 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-14 | $600.00K derived: sum of 2 quarters · filed 2024-11-14 | $900.00K 10-Q · filed 2024-11-14 | $1.60M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-12 | $600.00K 10-Q · filed 2024-08-12 | $1.30M derived: sum of 3 quarters · filed 2024-08-12 | $1.50M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-15 | $1.00M derived: sum of 2 quarters · filed 2024-05-15 | $1.20M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $900.00K derived: sum of 2 quarters · filed 2024-03-18 | $1.80M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $200.00K 10-Q · filed 2023-11-13 | $1.10M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |